OncoMed, Lilly Enter Clinical Supply Pact

OncoMed Pharmaceuticals, Inc. has entered into a clinical supply agreement with Eli Lilly and Co. to supply Alimta for OncoMed’s ongoing Phase II DENALI trial. The trial will evaluate Demcizumab, OncoMed’s anti-DLL4 antibody in combination with Lilly’s Alimta (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC).
 
Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or metastatic NSCLC for patients with non-squamous histology. The DENALI trial aims to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.
 
“This agreement with Lilly strengthens our efforts to investigate demcizumab as a key component alongside Alimta and platinum chemotherapy for the initial treatment of locally advanced or metastatic non-squamous non-small cell lung cancer,” said Paul J. Hastings, OncoMed’s chairman and chief executive officer. “These data will add to the growing body of research to determine whether certain three-drug combinations may help improve patient outcomes.”